Designing a peptide manufacturing facility requires careful consideration of reactor capacity, capabilities, and flexibility to meet current and future needs. The global CDMO Service for Peptide APIs market is projected to grow to US$ 13,186 million by 2032[reference:145], driving investment in new manufacturing facilities.
Key considerations in facility design include reactor sizes, material handling, purification capabilities, and quality control. Reactor sizes should span the range needed for current and anticipated projects, from small-scale R&D batches to large-scale commercial production. Material handling should support efficient transfer of solids and liquids while preventing contamination.
Purification capabilities are essential for peptide manufacturing. Preparative HPLC systems must be sized appropriately for the production scale, with sufficient capacity for the required throughput. Lyophilization capabilities must match the production scale, with appropriate shelf area and condenser capacity. Additional purification methods (ion exchange, size exclusion) may be needed for specific products.
Quality control laboratories must be equipped for comprehensive testing of starting materials, in-process samples, and final products. Analytical capabilities should include HPLC, mass spectrometry, and other techniques needed for peptide characterization. The laboratory should be designed to support efficient testing while maintaining sample integrity.
Flexibility is important in facility design to accommodate different products and processes. Modular design, flexible equipment, and multi-purpose areas enable efficient use of space and resources. At PeptideHub, our facility design includes dedicated GMP areas for synthesis, purification, and lyophilization, with full containment for potent compounds.